Loading clinical trials...
Loading clinical trials...
First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors
Conditions
Interventions
GEN1079
Locations
5
United States
START Midwest, LLC
Grand Rapids, Michigan, United States
START New York
Lake Success, New York, United States
Hospital Universitario San Pedro
Logroño, La Rioja, Spain
Hospital Universitario Fundacion Jimenez Diaz
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Start Date
April 7, 2026
Primary Completion Date
January 1, 2031
Completion Date
January 1, 2031
Last Updated
April 22, 2026
NCT07177937
NCT07360314
NCT07403721
NCT07539285
NCT07524348
NCT03093116
Lead Sponsor
Genmab
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions